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ABSTRACT 
Objective: To compare the effects on walking of Functional Electrical Stimulation (FES) 
and Ankle Foot Orthoses (AFO) for foot-drop of central neurological origin, assessed in 
terms of unassisted walking behaviours compared with assisted walking following a 
period of use (combined-orthotic effects). 
Data Sources: MEDLINE, AMED, CINAHL, Cochrane Central Register of Controlled 
Trials, Scopus, REHABDATA, PEDro, NIHR Centre for Reviews and Dissemination 
and clinicaltrials.gov. plus reference list, journal, author and citation searches. 
Study Selection: English language comparative Randomised Controlled Trials (RCTs). 
Data Synthesis: Seven RCTs were eligible for inclusion. Two of these reported different 
results from the same trial and another two reported results from different follow up 
periods so were combined; resulting in five synthesised trials with 815 stroke 
participants. Meta-analyses of data from the final assessment in each study and three 
overlapping time-points showed comparable improvements in walking speed over ten 
metres (p=0.04-0.95), functional exercise capacity (p=0.10-0.31), timed up-and-go 
(p=0.812 and p=0.539) and perceived mobility (p=0.80) for both interventions.  
Conclusion: Data suggest that, in contrast to assumptions that predict FES superiority, 
AFOs have equally positive combined-orthotic effects as FES on key walking measures 
for foot-drop caused by stroke. However, further long-term, high-quality RCTs are 
required. These should focus on measuring the mechanisms-of-action; whether there is 
translation of improvements in impairment to function, plus detailed reporting of the 
devices used across diagnoses. Only then can robust clinical recommendations be made.  
Key words: electrical stimulation therapy, nervous system diseases, stroke, walking, foot 
drop, systematic review, meta-analysis. 
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MAIN TEXT 
 
 
INTRODUCTION 
 
Conditions such as stroke, brain injury (BI), multiple sclerosis (MS), spinal cord injury (SCI) 
and cerebral palsy (CP) affect upper motor neuronal pathways (1) and are collectively 
referred to as pathologies of central neurological origin (CNO) (2). In the United Kingdom 
(UK) there are approximately 1.2 million people living with stroke (3), 100,000 MS and 
40,000 SCI (4), there are 160,000 BI admissions per year (5), and 1 in 400 people have CP 
(6). Foot-drop is a common impairment seen across these conditions (7) and although 
prevalence data in some of the CNO conditions is very limited, a commonly cited figure 
suggests that it is seen in 20-30% of people with stroke (7, 8) 
Foot-drop is categorized as an inability to dorsiflex the foot, with or without excessive 
inversion and is most commonly caused by weakness in the dorsiflexor (and evertor) and/or 
overactivity in the plantarflexor (and invertor) muscle groups. Foot-drop results in walking 
being slower, less efficient and potentially unsafe (7); as foot clearance during swing and 
initial foot contact at the start of the stance phase are compromised. These factors have been 
associated with an increased risk of falls (7), reduced quality of life (7, 9) and increased 
levels of mortality (10). 
Current practice in the treatment of foot-drop normally involves a form of ankle foot orthosis 
(AFO)(11). Functional electrical stimulation (FES) is also used but less frequently (9).  
4 
 
AFOs stabilise the foot and ankle and lift the toes when stepping (12). Meta-analyses have 
shown them to have positive effects on some aspects of walking (12, 13) but these analyses 
are primarily based on non-randomised control trial (RCT) evidence. AFOs have been 
criticised for detrimental effects on the adaptability of walking, propulsion, aesthetics and 
comfort (14-16) which can impact compliance and satisfaction.  
Foot-drop FES uses electrical pulse trains to stimulate the common peroneal nerve over key 
phases of  the gait cycle to correct the foot-drop impairment (17). This phasic stimulation can 
be delivered via surface or implanted electrodes. Foot-drop FES has been shown to have 
positive effects on walking speed (18, 19) but meta-analyses have also, in part, been based on 
non-RCT evidence. For surface systems, limitations have been cited in relation to issues with 
effort of setup, skin irritation and pain (20), which again affects compliance and satisfaction. 
Implanted systems address some of these limitations but are more costly (21). 
Despite their limitations both are endorsed in the management of foot-drop with clinical 
guidelines existing for AFO as a result of stroke (22, 23) MS (24), CP (25) and BI (26) and 
FES guidelines promoting use across all CNO diagnoses (2). However, these guidelines have 
had to rely on some non-RCT sources of evidence and as intervention specific guidelines, 
comparing to no treatment or physiotherapy, do not consider evidence from direct 
comparisons between these interventions. As a result current guidelines do not provide 
clinicians with a clear patient pathway. Recently a number of RCTs providing direct 
comparisons have been published. Furthermore, these studies have advanced our 
understanding of the effects these interventions may produce:   
a) Immediate-orthotic effects where same-day comparisons are made between AFO/FES 
unassisted and assisted walking behaviours  (16, 27).  
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b) Therapeutic effects (19, 28) where unassisted walking behaviours are compared with 
unassisted walking on a day some period later (16, 27).   
c) Training effects (16) where assisted walking behaviours are compared with assisted 
walking on a day some period later. 
d) Combined-orthotic effects (15) where unassisted walking behaviours on one day are 
compared with assisted walking on a day some period later (16, 27).  
 
The suggested mechanism-of-action for AFO is that the device remedies the loss of 
dorsiflexion/eversion by holding the foot in a neutral position but this can result in negative 
effects on neuromuscular control and muscle biomechanics with long-term use (29-31). 
Therefore, it has been assumed that they only provide immediate-orthotic effects (a) (12), a 
notion supported by the only known long-term AFO specific RCT in the field (32).  
In contrast, there are many reports of long-term neuromuscular control improvements with 
FES (19, 33) which are attributed to changes in neural plasticity, muscular strength and 
cardiovascular efficiency (31, 34, 35). The mechanism for these improvements has been 
hypothesised as being due to the coinciding of antidromic electrical stimulation-generated 
action potentials with volitional activity leading to strengthening of modifiable Hebb-
synapses at a segmental level (34, 36, 37).  
Given these proposed mechanisms-of-action it could be assumed that FES will provide a 
distinct advantage over AFO with long-term use. 
Two recent reviews (9, 38) have explored the long-term effects evidence for AFOs versus 
FES in stroke survivors; both concluding that there was a preference for FES but insufficient 
evidence to recommend one over the other. However, the first was not systematic (39) and 
included non-RCT studies (9) and the other did not meta-analyse; possibly due to the breadth 
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of question posed (38). This review (38) reported that FES was superior at conserving energy 
but included a paper where FES was combined with botulinum toxin (40) and another that 
compared FES to therapy as opposed to AFO (41).  
In order to provide improved clinical guidelines which will help clinicians determine which 
of these interventions to prescribe and what the directly comparable effects are over a period 
of use gold standard meta-analysis of RCT level evidence is required (42). Given that both 
interventions are most commonly prescribed as long-term orthotics (9, 30) and the 
assumption that studying long-term use will highlight any differences in walking behaviours 
resulting from the different mechanisms-of-action we sought to perform a systematic 
examination of the evidence base to address the question: 
Are the combined-orthotic effects on walking for foot-drop of CNO greater for FES than 
AFO? 
 
 
METHODS 
 
This review was designed according to the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) statement (43). The full review protocol can be found at: 
http://www.crd.york.ac.uk/PROSPERO/register_new_review.asp?RecordID=9892&UserID=
6114 
Nine electronic databases were searched. These were MEDLINE (Ovid), AMED (Ovid), 
CINAHL (EBSCO), Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, 
REHABDATA, PEDro, NIHR Centre for Reviews and Dissemination and clinicaltrials.gov. 
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A search strategy including controlled vocabularies related to “electric stimulation”, 
“walking” and “nervous system diseases” and terms such as “foot drop” and “electric* 
stimulat*” were used with no date limits (full search strategy available on request from the 
corresponding author). Reference list, citation, key author and journal searches were also 
completed and all searches were limited to the English language.  
Once duplicates were removed one reviewer (SP) screened titles and abstracts categorising 
each as ‘possibly’ or ‘clearly not’ relevant against the inclusion criteria (Table I). Full length 
articles were retrieved for ‘possibly relevant’ studies and two unmasked reviewers (SP and 
KH) independently assessed their eligibility (Table I) classing them as ‘relevant’, ‘definitely 
irrelevant’ or ‘unsure’. Different outcome measurements from the same trial reported in 
separate publications were treated as a single publication; as were separate publications that 
reported different data collection time-points within the same trial. Any disagreements or 
‘unsure’ publications were discussed (between SP and KH). A third reviewer was available to 
resolve any disagreements (LK). 
 
Table I. Inclusion Criteria. 
 
SP extracted data using a predesigned proforma; trial details extracted related to the 
characteristics of the included studies, participant and intervention details. Missing data 
and/or aspects that required clarification were requested from trial authors (14, 16, 44, 45), by 
SP (Appendix I). KH reviewed the extracted data for accuracy.  
 As an RCT-based review, and to avoid the limitations of scaled quality assessment tools (42, 
46), the Cochrane risk of bias assessment tool (42) was used independently by two reviewers 
(SP and KH) with a third reviewer (LK) available if necessary. To ensure impartiality, risk of 
8 
 
bias was based on published work only. Performance bias was not considered as the 
interventions precluded blinding of participants and measures were primarily objective (46).  
Outcomes across the World Health Organisation’s (WHO) International Classification of 
Functioning, Disability and Health (ICF) (47) were extracted. This helped to identify if there 
was any comparative evidence to support the assumed mechanisms-of-action and whether 
they translated into function. Therefore, all measurements were categorised as either being 
within the body functions and structures (BFS), activity or participation domain (47) by SP, 
using supporting literature (47-50).  All post-intervention data collection point assisted-
walking means and standard deviations (SD) were extracted with final-assessment data 
pooled for data analysis. Given the hypothesised mechanisms-of-action suggesting that FES 
would have greater benefits than AFO with longer-term use; broadly overlapping time-point 
data was also grouped for meta-analysis where possible. Standard errors were converted to 
SDs (14, 42, 51) and functional exercise capacity (an activity domain measurement (52)) was 
considered as metres walked so was converted as necessary (15).  
Meta-analyses were performed using RevMan 5.3® software. Where the same measurement 
was used across more than two trials, outcomes were combined using mean difference (MD) 
with 95% confidence intervals (CIs). Where an outcome was measured using different 
approaches, such as functional exercise capacity (distance walked in metres measured over 
two, three or six minutes), standardised mean difference (SMD) with 95% CIs was used. For 
crossover trials only pre-crossover data was extracted (15). Where there was more than one 
arm looking at the same intervention the similarity at baseline to the other intervention and 
size were used to decide which to use and the data from the most comparable group extracted 
(15).  
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Heterogeneity was examined using visual inspection of forest plot, chi² test and I² statistic. If 
the chi² test showed heterogeneity which the I² statistic identified as being moderate to low, 
(<50% (42)) a fixed-effects model was used. A random-effects model was used for 
heterogeneity of >50%. 
 
 
RESULTS 
 
1836 citations were found of which seven were eligible for inclusion. Two of these reported 
outcomes from the same participants (44, 53) so were grouped, and subsequently referred to 
by the first publication date (44). One trial published results up to six months (14) and had 
another publication reporting results at 12 months (51); so were also grouped. For meta-
analysis the relevant publication was used with the source identified by the date of the 
publication on the corresponding forest plot. Thus a total of five RCTs, published between 
2007 and 2015 with 815 participants, were available for meta-analysis (Fig. 1).  
 
Fig. 1. Flowchart of trial selection. 
 
Table II. Characteristics of included trials, participant and intervention details. 
 
 
Characteristics of included trials 
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One trial used a multiple-site crossover design (15) with two AFO arms. Data from arm 2 
(AFO-FES) was used as it was larger and similar to the FES group at baseline. The remaining 
four trials used two arm parallel RCT design, two single-site (44, 45) and two multiple-site 
(14, 16) (Table II). 
 
Participant details 
 
All the participants were over the age of 18 years and had suffered a stroke. Average time 
since diagnosis ranged from 51.7 days (45) up to 6.9 years (14, 51). Of those trials that 
reported hemiplegic side (16, 44, 45) there was a relatively even distribution (116:47.9% 
right, 126: 52.1% left). Two of the trials recruited current AFO users (16, 44) whereas the 
remaining four introduced the interventions to both groups for the first time (Table II).  
 
Intervention details 
 
Three of the trials (14-16, 51) reported providing “customized” AFOs prescribed by an 
orthotist; plus a physiotherapist for Kluding et al (16). One used off-the-shelf AFOs (45) 
which is appropriate practice with their, sub-acute, population (54) and one used a 
combination (44). No trial reported any further details of the AFOs or how prescription 
decisions were made; none were hinged. All-but-one study used surface FES systems (44), 
one trial highlighted that “clinicians” setup FES for measurement (45) but no trial reported 
details of setup parameters such as electrode placement, ramping, amplitude or frequency. 
The setting where interventions were used varied with participants from three of the studies 
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using the devices within their own environment (14, 15, 44, 51). One trial used them in both 
the participants own environment and under supervision (16) and one used them only under 
supervision (45). All-day-use was encouraged in all-but-one of the trials (45), some with a 
gradual introduction, although whether this was adhered to was not reported. Three trials 
provided concurrent therapy for both groups (16, 44, 45) (Table II). 
 
Methodological Quality 
 
Table III. Risk of Bias 
 
Table III summarises the quality assessment, Kluding et al (16) alone had no identified areas 
of high risk of bias. 
 
Table IV. Outcome measurements and intervention effects 
 
 
Outcome Measurements 
All trials utilised ICF activity domain measurements; most commonly the 10-metre walk test 
(Table IV). However, one did not collect any BFS domain measurements (14, 51) and 
another lacked participation domain measurements (15). The intervention period studied 
ranged from six weeks (15) – 12 months (51). 
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To allow direct comparison of the assumed mechanisms-of-action and functional translation 
the following results are presented according to ICF domains. The narrative comparison 
found in Table IV is summarised below. Final-assessment meta-analyses are presented first. 
There were three overlapping data time-points found at 4-6 weeks, 12-13 weeks and 26-30 
weeks for activity domain measurements. These are categorised as short, medium and longer-
term respectively (Table IV); meta-analyses at these time-points are then presented. 
 
BFS 
 
Physiological cost index (PCI) (15), cadence (45), spatiotemporal/kinematics (44) and lower 
limb Fugl-Meyer (16) were reported by single trials; therefore pooled-analysis was not 
possible. All the trials found within-group improvements but no significant statistical 
differences were reported for any of these measures by the primary authors except Kottink et 
al (44) who found some spatiotemporal and kinematic differences in favour of FES (p<0.05) 
(Table IV).  
 
Activity 
 
Final-assessment outcomes of 10-metre walking speed (all five trials, n=789) and functional 
exercise capacity (three trials, n=761) were pooled. Meta-analysis showed between-group 
comparable improvement (MD= 0.01, [-0.04, 0.05]; I2=0%; p=0.79, Fig. 2a); and SMD -0.07 
[0.22, 0.07], I2=0%; p=0.31, Fig. 3a) respectively. 
 
13 
 
Fig. 2. Activity domain measurement: 10-metre (m) walk test metres per second (m/s)  
 
Fig. 3. Activity domain measurement: functional exercise capacity metres (m).  
 
The timed up-and-go test was used in two trials (16, 51), both reported between-group 
comparable improvement (p=0.812 and p=0.539), therefore meta-analysis was not required 
(Table IV).  
All other final-assessment activity measures were used in single trials with between-group 
comparable improvement in all cases (Table IV).  
Meta-analysis was possible for the 10-metre walk test using data at short (four trials, n=771), 
medium (three trials, n=699) and longer-term (three trials, n=713) time-points (Fig. 2b-d). It 
revealed comparable improvement in the short-term (MD= 0.02 [-0.05, 0.10]; I2=66%; 
p=0.54, Fig. 2b)) and longer-term (MD= -0.00 [-0.04, 0.04]; I2=14%; p=0.95, Fig. 2d)). In 
the medium-term there was a marginal, but significant, difference in favour of AFO (MD= -
0.04 [-0.09,-0.00]; I2=0%; p=0.04, Fig. 2c)). 
Functional exercise capacity meta-analyses were performed for short (three trials, n=761) and 
medium-term (two trials, n=692) time-points (Fig. 3b and c). Meta-analyses revealed 
between-group comparable improvement (SMD= -0.12 [-0.26-0.02]; I2=0%; p=0.10, Figure 
3b) and SMD= -0.10 [-0.25, 0.05]; I2=0%; p=0.19, Fig. 3c)). 
 
Participation 
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The mobility domain of the Stroke Impact Scale (SIS) was collected by three trials (n=701) 
(14, 16, 45). Meta-analysis showed between-group comparable improvement (MD 0.31 [-
2.06, 2.68]; I2=41%; p=0.80, Fig. 4). 
 
Fig. 4. Participation domain measurement: Stroke Impact Scale (mobility sub-scale). 
 
Activity monitoring was used by two trials (16, 44) (Table IV) but their data collection 
methods varied too significantly (steps taken compared to time spent in different positions) to 
pool results. Kluding et al (16) found no significant differences in the number of steps taken 
and Kottink et al (44) found the FES group spent significantly more time in sitting/lying than 
the AFO group (p=0.04).  
All other final-assessment participation measurements were used by a single trial (14) with 
between-group comparable improvements found (Table IV).  
 
 
DISCUSSION 
 
This is the first systematic review, including meta-analysis, of studies comparing AFO to 
FES as interventions for people with CNO foot-drop which focusses on the clinically relevant 
combined-orthotic effects on walking. As a RCT-based review with meta-analysis guided by 
the PRISMA statement (55) the results provide the highest level of evidence currently 
available to support clinical decision making (42).  
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The RCTs were deemed to be of medium-methodological quality, which provides some 
confidence in our results that both interventions demonstrate equal combined-orthotic 
improvements in 10-metre walking speed, functional exercise capacity, timed-up-and-go and 
the mobility sub-scale of the SIS; regardless of the length of time used.  
Given the different hypothesized mechanisms-of-action detailed in the introduction it is 
somewhat surprising that there was no differentiation between the two interventions for any 
of the pooled measurements.  To explore this result we examined outcome measurements 
within the BFS domain (which directly reflect mechanisms-of-action (48)) and whether or not 
these changes in BFS coincide with changes in activity and participation differentially 
between the interventions and over different time-points of use. 
 
BFS 
 
 The majority of measurements used in the reviewed trials suggest that there are no 
differences between the two interventions. However, given the suggestions of a negative 
influence of AFO and a positive influence of FES on volitional muscle activation it was 
surprising that none of the included trials reported electromyography (EMG) or strength data. 
Throughout our systematic search of the literature we found only one RCT (which explored 
therapeutic as opposed to combined-orthotic effects) which compared EMG activity between 
FES and AFO treatments. This trial reported that EMG activity was greater following a 
period of FES than AFO use (56).  
Kottink et al (53) was the only reviewed trial to measure gait features and found differences 
between a FES group and an AFO group. Despite these findings, that are supported by results 
of non-RCT studies (57-61), no further inferences can be drawn at this time. Future trials 
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should capture such measurements to determine whether restorative as opposed to 
compensatory changes are made (62) in order to more accurately understand the mechanisms-
of-action. 
 
Activity & Participation 
 
Meta-analysis of three validated measures of the activity domain (49, 52) and one mobility 
specific participation domain measurement (49, 52) indicate that AFOs and FES produce 
equivalent functional improvements to walking for people with foot-drop as a result of 
stroke; regardless of length of use.  The equivalency of effects between these interventions is 
supported by non-RCT studies which have found no significant changes in activity domain 
measurements when FES is provided to AFO users (59, 60, 63).  
Given the difference in hypothesized mechanisms-of-action between FES and AFO and the 
lack of BFS measurements, the question remains as to how these comparable effects on 
activity/participation are achieved. One explanation is that both simply correct the 
mechanical problem of foot-drop; as is suggested for AFO. However, this does not fully 
explain the differences between immediate-orthotic effect and orthotic effect after a period of 
use. The activity monitoring results from one trial highlight another potential explanation. 
Kluding et al (16) found that the number of steps taken per day increased with use of either 
intervention (1891-2069, AFO and 2092-2369, FES at six and 30 weeks). This increase in 
repetition of walking in both FES and AFO intervention groups (facilitated by the correction 
of foot-drop) could explain the observed comparable improvements. Indeed intensity of task-
specific repetition is widely accepted as critical for effective improvements of motor-
impairments (64-66). This hypothesis is consistent with Kluding et al’s suggestion that both 
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interventions achieve combined-orthotic effects through immediate-orthotic and training 
effects (16).  
A final hypothesis is that RCTs to date have not been long enough to detect differences given 
the predominantly chronic populations investigated (67). Bethoux et al (51) did not find 
differences at 12 months which may suggest even longer-term follow up is required (68).  To 
facilitate comparisons all future trials should ensure that data collection time-points are 
justified against physiological processes underlying treatment effects. 
This review had some limitations. Firstly, it has revealed that until 2007 research has been 
limited to examinations of a single intervention for a single diagnosis precluding comparisons 
between interventions which might usefully inform clinicians which intervention may be 
most suitable. Since 2007 comparative RCTs have been undertaken, making this review 
timely. Whilst future FES (9, 69) and AFO specific studies (13, 70, 71) are necessary for 
intervention development, where possible, research should be impairment focused in order to 
facilitate more discerning prescription.  
Secondly, despite the literature search encompassing all CNO diagnoses, the reviewed trials 
only included participants who had experienced a stroke and who were over the age of 18 so 
our results can only be applied to this population. Trials using different CNO populations are 
necessary given that current clinical guidelines encompass them. Similarly, in order to form 
clinical guidelines indicating which subgroups of patients with any given CNO diagnosis 
(e.g. time points post-stroke, severity of foot-drop impairment) might benefit most from 
either intervention future studies with carefully defined inclusion/exclusion criteria are 
needed.  This approach is of critical importance in subsequent trials so that potentially 
important clinical effects are not diluted in heterogeneous study groups. Until such a time as 
sufficient high-quality RCTs in specific groups of patients become available any meta-
analyses will also suffer similar limitations.  
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Thirdly, risk of bias was present in the reviewed studies with detection bias (assessor 
blinding) the most common area. While this might impact our results this area of bias is 
common within rehabilitation research. Indeed, previous FES (28) and AFO (12) reviews 
have chosen to discount it, suggesting it is impractical to address in studies of medical 
devices. It can also be argued that objective measures minimize the risk of this source of bias. 
However, two trials (15, 16) attempted to control for this, suggesting that it is feasible to 
blind assessors and should at least be considered in future trials (72).  We based the quality 
assessment on published material alone; so as not to advantage trial authors who respond to 
requests for additional data. Therefore a lack of reported methodological detail might account 
for some of the other unclear and high areas of bias found. 
Finally, the reader should note that a range of different AFO and FES devices were used in 
the included trials and our analysis combined these. While combining data from different 
types of AFO/FES does not allow a detailed look at the possible different effects of each 
individual sub-type, assuming the prescription of devices within each trial was provided on 
the basis of clinical judgement and complies with current guidelines, this allows for a 
clinically relevant comparison. Furthermore, limited reports of the details of AFO and FES 
interventions preclude reliable sub-group analyses. The traditional description of AFOs on 
the basis of the material used (carbon fibre, plastic, metal) or mode of manufacture 
(customized versus off-the-shelf (54) as with our included trials) should be discontinued. The 
mechanical properties (stiffness, mass) of an AFO determine its behaviour (73) so it is these 
that should be measured and reported (73-75). Similarly, differences in outcome between 
therapist and patient FES setup have been found (76, 77) so this should also be reported. 
None of the included trials reported details of FES setup parameters and it remains unclear 
which set of parameters would be most useful when comparing across trials; further work is 
required in this area.  
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In conclusion, despite very different hypothesised mechanisms-of-action for AFO and FES 
this RCT, state-of-the-art review, with meta-analysis (39) conservatively indicates that AFOs 
have positive combined-orthotic effects on walking that are equivalent to FES for foot-drop 
caused by stroke. Methodological and reporting limitations within the current RCT pool 
preclude clinical recommendations regarding which type of AFO or FES set-up to use for 
particular patient groups from being made; as they do in guiding clinicians which 
intervention to prescribe for a specific patient. However crucially, and for the first time, 
barriers to achieving such clinical recommendations within research design and reporting 
have been identified to progress future research. Furthermore long-term, high-quality RCTs 
are required across CNO diagnoses. These should focus on measuring the mechanisms-of-
action, whether there is translation of improved impairment to function and reporting the 
correct device details; only then will discerning prescription be possible. 
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Table I. Inclusion Criteria. 
Design • Randomised Controlled Trials (RCT) 
Participants • Participants with foot-drop of a central neurological origin 
Intervention • Common peroneal nerve FES to address the specific impairment of foot-drop, 
with or without other areas of stimulation • Stimulation eliciting a muscular contraction • Trials where common peroneal stimulation is used during walking (overground 
or treadmill) as part of the intervention  • Trials studying combined-orthotic effects of foot-drop FES • Trials where foot-drop FES and another intervention are used in combination but 
foot-drop FES is measured independently 
Comparator • Trials comparing foot-drop FES with AFO (the term therapy was allowed as 
might involve AFO) 
Outcomes • Measures of walking 
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Table II. Characteristics of included trials, participant and intervention details. 1 
Abbreviations: FES= functional electrical stimulation; AFO=ankle-foot orthosis; *=post intervention/dropout characteristics; +=ITT completed; ~=based on 2007 not 2012 data; †= Pre intervention/drop out 2 
characteristics;  CVA= Cerebrovascular accident/Stroke; ** post intervention/drop characteristics at later time point than is included in this review (12 weeks); yrs=years; mos=months; Customized= custom made/ 3 
modified AFO; Combination= Different AFOs used by different participants; off the shelf= prefabricated/unmodified AFO; ***= both groups continued with physical therapy alongside intervention; TENS= 4 
transcutaneous electrical nerve stimulation with no motor response; wk=week; NESS L300=Bioness model; ODFS= Odstock foot-drop system; AD=all day.  5 
 6 
 7 
 8 
  Trial design N 
Diagnosis 
(R):(L) 
Men: Women  Age (years)  Time since 
diagnosis  
Current or 
new AFO 
users 
AFO Mechanical 
properties 
reported 
FES  Setup for 
measurement done 
by 
Use 
Bethoux (2014 & 
2015)+  
2 arm parallel 
Multiple sites 
495 (242 FES: 
253 AFO)  
CVA 
Not specified 
 
FES=147:95 
AFO=157:96 
FES=63.87 
(11.33) 
AFO=64.3 
(12.01) 
FES=6.9yrs 
(6.43) 
AFO=6.86yrs 
(6.64) 
New  Customized   
 
No  Surface 
Walkaide 
Not specified Home 
2wk progressive wearing schedule 
then AD 
Everaert (2013)* 3 arm crossover 
Multiple sites 
 
78 (43 FES: 35 
AFO)  
CVA 
Not specified 
FES=32:6** 
AFO=19:12** 
FES=57.1  
(12.9)**  
AFO=55.6 
(11.9)** 
FES=6.4mos 
(3.8)** 
AFO=6.9mos 
(3.2)** 
New  Customized 
 
No  Surface 
Walkaide 
Not specified Home 
AD 
Kluding (2013)+ 2 arm parallel 
Multiple sites 
197 (99 FES: 98 
AFO)  
CVA 
93:104 
FES=51:48 
AFO=67:31 
FES=60.71 
(12.24) 
AFO=61.58 
(10.98) 
FES=4.77yrs 
(5.29) 
AFO=4.34yrs 
(4.1) 
Current  Customized*** 
PLUS TENS for 
2wks 
 
No  Surface 
NESS L300 
Not specified Both • Bioness clinical 
protocols followed 
15mins-AD • Training: 15mins x2 day 
1wk then 20mins 2xday 
next 2wks 
Kottink (2007)*~ 2 arm parallel 
Single site 
29 (14 FES: 15 
AFO)  
CVA 
13:16 
FES=10:04 
AFO=10:05 
FES=55.2 
(11.36) 
AFO=52.87 
(9.87) 
FES=9.07yrs 
(9.29) 
AFO=5.67yrs 
(4.64) 
Current  Combination*** 
 
No  Implanted 
2-channel 
implant 
Not specified Home 
Gradual increase over 2wks, then 
AD 
 
Salisbury (2013)† 2 arm parallel 
Single site 
16 (9 FES: 7 
AFO)  
CVA 
10:6 
 
FES=03:06 
AFO=03:04 
FES=55.8 
(11.3) 
AFO=52.6 
(17.2) 
FES=51.7 
days (34.6) 
New  Off the shelf *** No  Surface 
ODFS 
Clinician for FES Supervised 
Part of physiotherapy 20mins, 5 x 
wk with supervised/ independent 
walking as appropriate. 
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Table III. Risk of Bias. 9 
Abbreviations: L= Low; U=Unclear; H=High. 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 Random sequence 
generation  
(selection bias) 
Allocation concealment 
(selection bias) 
Blinding of 
outcome 
assessment  
(detection bias) 
Incomplete outcome 
data (attrition bias) 
Selective reporting 
(reporting bias) 
Other 
bias 
Bethoux 
2014/2015 
U H H L L L 
Everaert 2013 U U U H L L 
Kluding 2013 L L U L U L 
Kottink 2007 H U H U L L 
Salisbury 
2013 
H L H U L L 
28 
 
Table IV. Outcome measurements and intervention effects. 22 
 23 
  Walking outcome measures used & ICF level  Outcome collection 
points  
Combined-orthotic effects  
Bethoux et al 
(2014/2015+) 
Activity: • 10MWT1 • 6min walk test (distance)   • Gaitrite Functional Ambulation Profile+ • mEFAP (including TUG) 
Participation+: • SIS (Mobility, ADL/IADL & social participation domains 
combined)1  • SIS mobility sub-scale  • Perry ambulation categories based on 10MWT results 
 
0  
Short:1mos (not published) 
Medium: 3mos (not 
published)  
Long:6mos 
12 mos+ 
• FES=AFO 
Everaert et al (2013) BFS:  • PCI over 4min test1 
Activity:  • 4min walking test (speed)1 • 10MWT  • Modified RMI 
0, 3wks  
Short: 6wks 
• Modified RMI: between-
group, post-intervention 
differences not reported  • FES=AFO: for other 
measures 
Kluding et al (2013) BFS:  • LL Fugl Meyer 
Activity:  • 10MWT (self and fast)1 • TUG • 6min walk test (distance)  
Participation: • SIS mobility sub-scale • Activity monitoring (Stepwatch ®) 
0 
Short: 6 weeks 
Medium: 12 weeks 
Long: 30wks (only change 
data published) 
• FES=AFO 
Kottink et al (2007) BFS:  • stride time* • stride length*  • stride width*  • step length*  • stance phase %* • 1st double support phase %*  • 1st single support phase %*  • kinematics=hip, knee & ankle* 
Activity:  • 10MWT • 6min walk (speed) • Speed* 
Participation: 
0  
Long: 26wks 
• FES>AFO: Longer 1st 
single support phase %*; 
shorter Stance phase; 1st 
double support phase 
%*; Speed*; 10MWT; 
6min walk (speed) at 26 
wks • AFO spent less time less 
in sitting/lying than FES • FES=AFO: all other 
measures 
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• Activity monitoring (ActivPAL®) 
Salisbury et al (2013) BFS: • Cadence (10MWT) 
Activity:  • Speed (10MWT) • FAC 
Participation: • SIS mobility sub-scale 
 
0  
Short: 6wks  
Medium: 12wks 
• FES=AFO 
 
Abbreviations: wks=weeks; mos=months; min(s)=minute(s); mEFAP=modified Emory Functional Ambulation Profile; TUG=Timed Up and Go; QoL=Quality of Life; SIS=Stroke Impact Scale; ADL/IADL= 24 
Activities of Daily Living/ Instrumental Activities of Daily Living; 10MWT=10-metre walk test; PCI=Physiological Cost Index; RMI=Rivermead Mobility Index; BBS=Berg Balance Scale; *=from Kottink et al 25 
(2012); FAC=Functional Ambulation categories; 1=identified as primary outcome measure by authors; += not reported in Bethoux 2015 12 month follow up publication; =increase; >=greater than; = =equal to; <=less 26 
than. 27 
 28 
 29 
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Fig. 1. Flowchart of trial selection. 30 
 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
Records identified through database searching  
(n = 1593) 
 
MEDLINE 690  CINAHL176 AMED 162  
PEDro 76  CENTRAL 161 clinicaltrials.gov 36 
Naric 189  Scopus 103 
 
Additional records identified 
through other sources  
(n = 243) 
Records after duplicates/obviously irrelevant removed  
(n =703) 
Records screened by titles and 
abstract  
(n = 703) 
Records excluded  
(n =635) 
Reasons include: non-RCT design, not peroneal 
stimulation, not FES, participants were healthy, 
not exploring walking, non-human, technical or 
surgical exploration 
Full-text articles assessed for 
eligibility  
(n = 68) 
Full-text articles excluded  
(n =62) 
 
Many had multiple reasons:- 
Not combined-orthotic effects: 43 
Not RCT: 17 
Not foot-drop: 13 
Not peroneal nerve: 10 
Not functional during walking: 9 
Walking not measured: 6 
Sensory stimulation: 5 
Only FES setups or healthy comparisons: 2 
Potentially relevant: 1 
 
Studies included in narrative & 
quantitative synthesis 
(Meta-analysis)  
(n = 7, 2x2 combined so n=5) 
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Fig. 2. Activity measure: 10-metre (m) walk test metres per second (m/s). 55 
 56 
 57 
2a) Final-assessment 58 
 59 
2b) Short-term. Bethoux et al (2014) and Kluding et al (2013) data obtained via 60 
correspondence with authors 61 
 62 
2c) Medium-term. Bethoux et al (2014) and Kluding et al (2013) data obtained via 63 
correspondence with authors 64 
 65 
2d) Longer-term. Kluding et al (2013) data from correspondence with authors 66 
 67 
 68 
 69 
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Fig. 3. Activity measure: Functional exercise capacity metres (m). 70 
 71 
3a) Final-assessment. Kluding et al (2013) data obtained via correspondence with authors. 72 
 73 
3b) Short-term. Bethoux et al (2014) and Kluding et al (2013) data obtained via 74 
correspondence with authors 75 
 76 
3c) Medium-term. Data obtained via correspondence with authors 77 
 78 
 79 
 80 
 81 
 82 
 83 
 84 
 85 
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Fig. 4. Participation measure: Stroke Impact Scale (mobility sub-scale). 86 
 87 
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APPENDIX I 88 
Unpublished data  89 • Salisbury et al (45) published results were a combination of assisted and unassisted 90 
walking data. On request assisted data was provided.  91 
• Kluding et al (16) published change as opposed to post-intervention data, this was 92 
provided on request.  93 
• Kottink et al (44) only displayed results from their 2007 study in graphical form and 94 
did not respond to request for raw data.  95 
• Bethoux et al (14) published standard error, these were converted to SD (42).  96 
• Both Bethoux et al (14) and Kluding et al (16) provided unpublished time-point data 97 
on request.  98 
• Functional exercise capacity was converted from the speed (metres per second) for 99 
Everaert et al (15). 100 
 101 
 102 
 103 
 104 
 105 
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